KALA Kala Pharmaceuticals, Inc. Stock Quote

KALA [NASD]

Index	-	P/E	-	EPS (ttm)	-2.09	Insider Own	2.20%	Shs Outstand	56.03M	Perf Week	-1.07%
Market Cap	418.31M	Forward P/E	-	EPS next Y	-1.75	Insider Trans	0.00%	Shs Float	55.43M	Perf Month	-0.27%
Income	-95.20M	PEG	-	EPS next Q	-0.46	Inst Own	81.40%	Short Float	17.04%	Perf Quarter	-2.24%
Sales	5.30M	P/S	78.93	EPS this Y	-10.60%	Inst Trans	0.53%	Short Ratio	5.10	Perf Half Y	-27.55%
Book/sh	1.89	P/B	3.93	EPS next Y	8.90%	ROA	-43.10%	Target Price	-	Perf Year	2.77%
Cash/sh	2.83	P/C	2.63	EPS next 5Y	-	ROE	-93.70%	52W Range	5.04 - 14.68	Perf YTD	9.59%
Dividend	-	P/FCF	-	EPS past 5Y	-27.10%	ROI	-87.40%	52W High	-49.39%	Beta	0.43
Dividend %	-	Quick Ratio	8.70	Sales past 5Y	67.90%	Gross Margin	51.70%	52W Low	47.42%	ATR	0.29
Employees	136	Current Ratio	9.10	Sales Q/Q	46.70%	Oper. Margin	-	RSI (14)	51.02	Volatility	2.52% 4.48%
Optionable	Yes	Debt/Eq	0.68	EPS Q/Q	26.50%	Profit Margin	-	Rel Volume	0.82	Prev Close	7.46
Shortable	Yes	LT Debt/Eq	0.68	Earnings	Nov 05 BMO	Payout	-	Avg Volume	1.85M	Price	7.43
Recom	1.70	SMA20	1.46%	SMA50	0.45%	SMA200	-19.51%	Volume	1,516,192	Change	-0.40%

Sep-14-20

Downgrade

Jefferies

Buy → Hold

$10

Jul-23-20

Initiated

Northland Capital

Outperform

Jun-01-20

Resumed

Oppenheimer

Outperform

$21

May-27-20

Reiterated

H.C. Wainwright

Buy

$14 → $17

Mar-09-20

Upgrade

BofA/Merrill

Neutral → Buy

Dec-17-19

Downgrade

BofA/Merrill

Buy → Neutral

$9 → $6

Mar-14-19

Initiated

Jefferies

Buy

$15

Jan-20-21 04:01PM	Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jan-07-21 07:00AM	Kala Pharmaceuticals Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline Business Wire
Jan-04-21 08:00AM	Kala Pharmaceuticals to Present at Upcoming Investor Conferences in January Business Wire
Dec-27-20 02:39AM	Investors Who Bought Kala Pharmaceuticals (NASDAQ:KALA) Shares A Year Ago Are Now Up 105% Simply Wall St.
Dec-18-20 04:01PM	Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Dec-16-20 03:51PM	Is KALA A Good Stock To Buy Now? Insider Monkey
Nov-27-20 01:39AM	Kala Pharmaceuticals (NASDAQ:KALA) Has Debt But No Earnings; Should You Worry? Simply Wall St.
Nov-18-20 04:05PM	Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Nov-16-20 07:00AM	Kala Pharmaceuticals Provides Update on Launch Plans for EYSUVISTM for the Treatment of Dry Eye Disease Business Wire
Nov-11-20 08:00AM	Kala Pharmaceuticals to Present at the Jefferies 2020 Virtual London Healthcare Conference Business Wire
Nov-05-20 08:45AM	Kala Pharmaceuticals (KALA) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:00AM	Kala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update Business Wire
06:15AM	Kala Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Oct-29-20 08:17PM	Kala Pharmaceuticals Got Its FDA Approval: Whats Next for the Stock TipRanks
12:34PM	Kala Pharmaceuticals (KALA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
08:00AM	Kala Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call Business Wire
Oct-28-20 10:24AM	Biotech Stock Roundup: GILD's Veklury Approved, NVAX Provides Vaccine Update & More Zacks +5.98%
06:21AM	Analysts Just Made A Major Revision To Their Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Revenue Forecasts Simply Wall St.
Oct-27-20 03:38PM	Why Kala Pharmaceuticals Stock Sank Today Motley Fool -18.72%
11:22AM	Kala Pharma Tumbles Despite FDA Approval of Dry Eye Drug TheStreet.com
07:00AM	Kala Pharmaceuticals Announces FDA Approval of EYSUVIS for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease Business Wire
Oct-19-20 04:05PM	Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Oct-15-20 11:06AM	Hedge Funds Are Piling Into Kala Pharmaceuticals, Inc. (KALA) Insider Monkey
Oct-08-20 08:50AM	Is the Options Market Predicting a Spike in Kala Pharmaceuticals (KALA) Stock? Zacks
Oct-06-20 08:48AM	Kala Pharmaceuticals (KALA) Looks Good: Stock Adds 6% in Session Zacks +6.16%
Oct-05-20 10:15AM	3 Strong Buy Healthcare Stocks With Major Catalysts Approaching TipRanks +5.99%
Sep-30-20 10:01AM	What Kind Of Investors Own Most Of Kala Pharmaceuticals, Inc. (NASDAQ:KALA)? Simply Wall St. -5.42%
Sep-18-20 04:05PM	Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire +12.47%
Sep-10-20 08:00AM	Kala Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Dry Eye Disease and Potential for EYSUVIS Business Wire
Sep-08-20 08:00AM	Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September Business Wire
Aug-27-20 11:00AM	Have Insiders Been Buying Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Shares? Simply Wall St.
Aug-07-20 09:26AM	Did Hedge Funds Make The Right Call On Kala Pharmaceuticals, Inc. (KALA)? Insider Monkey
Aug-06-20 09:15AM	Kala Pharmaceuticals (KALA) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:00AM	Kala Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update Business Wire
Aug-04-20 08:00AM	Kala Pharmaceuticals to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference Business Wire
Jul-30-20 04:01PM	Kala Pharmaceuticals to Report Second Quarter 2020 Financial Results and Host Conference Call Business Wire
Jul-28-20 01:01PM	How Much is Kala Pharmaceuticals' (NASDAQ:KALA) CEO Getting Paid? Simply Wall St.
12:33PM	Kala Pharmaceuticals (KALA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Jul-17-20 04:01PM	Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jun-23-20 11:01AM	Hedge Funds Have Never Been This Bullish On Kala Pharmaceuticals, Inc. (KALA) Insider Monkey -5.35%
Jun-10-20 08:00AM	Kala Pharmaceuticals Announces Virtual-Only Format for 2020 Annual Meeting of Stockholders Business Wire
Jun-05-20 11:30AM	Is Kala Pharmaceuticals (KALA) Stock Outpacing Its Medical Peers This Year? Zacks
Jun-02-20 08:41AM	JPMorgan: 2 Stocks to Buy for At Least 40% Upside Potential (And 1 to Avoid) TipRanks
May-28-20 08:16AM	Need To Know: Analysts Are Much More Bullish On Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Revenues Simply Wall St.
May-27-20 08:00AM	Kala Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference Business Wire
May-26-20 11:41AM	Top Ranked Momentum Stocks to Buy for May 26th Zacks
08:00AM	Kala Pharmaceuticals Announces FDA Acceptance of New Drug Application for EYSUVIS for Dry Eye Disease Business Wire
May-19-20 11:30AM	Has Kala Pharmaceuticals (KALA) Outpaced Other Medical Stocks This Year? Zacks
May-09-20 10:01PM	Kala Pharmaceuticals, Inc. (KALA) Q1 2020 Earnings Call Transcript Motley Fool
May-07-20 10:05AM	Kala Pharmaceuticals (KALA) Reports Q1 Loss, Misses Revenue Estimates Zacks
08:23AM	Kala Pharmaceuticals: Q1 Earnings Insights Benzinga
07:00AM	Kala Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update Business Wire
May-06-20 08:00AM	Kala Pharmaceuticals to Present at BofA Securities 2020 Health Care Conference Business Wire +10.04%
May-05-20 12:00PM	Kala Pharmaceuticals (KALA) Is Up 2.56% in One Week: What You Should Know Zacks
09:03AM	Kala Pharmaceuticals' Shares March Higher, Can It Continue? Zacks
May-04-20 08:00AM	Kala Pharmaceuticals Resubmits New Drug Application for EYSUVIS for Dry Eye Disease Business Wire +10.07%
May-01-20 11:30AM	Is Kala Pharmaceuticals (KALA) Stock Outpacing Its Medical Peers This Year? Zacks
Apr-30-20 08:00AM	Kala Pharmaceuticals to Report First Quarter 2020 Financial Results and Host Conference Call Business Wire -6.65%
Apr-17-20 04:01PM	Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire +10.20%
Apr-16-20 12:00PM	Here's Why Momentum Investors Will Love Kala Pharmaceuticals (KALA) Zacks
Apr-08-20 11:01AM	The Zacks Analyst Blog Highlights: DHT, Summit Therapeutics, Sharps Compliance, Frontline and Kala Pharmaceuticals Zacks
10:42AM	Zacks.com featured highlights include: Kala Pharmaceuticals, Unicharm and Capcom Zacks
Apr-07-20 11:30AM	Has Kala Pharmaceuticals (KALA) Outpaced Other Medical Stocks This Year? Zacks
Apr-03-20 04:01PM	Kala Pharmaceuticals Announces Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Mar-20-20 08:30PM	13D Filings Barrons.com
Mar-15-20 04:24PM	Insiders Roundup: Masimo, Hertz GuruFocus.com
Mar-11-20 11:06AM	Biotech Stock Roundup: NVAX, CANF Up on Coronavirus Treatment Updates & More Zacks
10:50AM	Oppenheimer: These 3 Stocks Are Ripe for Double-Digit Gains TipRanks
Mar-10-20 11:02PM	Kala Pharmaceuticals Announces Pricing of Public Offering of 16,000,000 Shares of Common Stock Business Wire
04:44PM	Kala Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
11:30AM	Is Kala Pharmaceuticals (KALA) Outperforming Other Medical Stocks This Year? Zacks
09:31AM	Kala Pharmaceuticals, Inc. (KALA) Shares March Higher, Can It Continue? Zacks
09:24AM	Top Ranked Momentum Stocks to Buy for March 10th Zacks
Mar-09-20 06:00AM	Kala Pharmaceuticals Announces Statistically Significant Results for Primary and Key Secondary Endpoints in STRIDE 3 Clinical Trial Evaluating EYSUVIS for Signs and Symptoms of Dry Eye Disease Business Wire +26.27%
Mar-06-20 10:11AM	Implied Volatility Surging for Kala Pharmaceuticals (KALA) Stock Options Zacks
Feb-20-20 04:01PM	Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Feb-12-20 11:30AM	Has Kala Pharmaceuticals (KALA) Outpaced Other Medical Stocks This Year? Zacks
08:35AM	Kala Pharmaceuticals (KALA) Reports Q4 Loss, Lags Revenue Estimates Zacks
07:00AM	Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results Business Wire
Feb-09-20 03:22PM	The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight Benzinga
Feb-06-20 11:53AM	Biogen Soars on Patent Win for MS Drug Tecfidera Over Mylan Zacks +9.74%
08:00AM	Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call Business Wire
Feb-03-20 11:11AM	Aimmune's Palforzia Wins FDA Approval for Peanut Allergy Zacks +8.89%
Jan-30-20 11:10AM	Intercept (ICPT) Concludes Enrollment in Study on NASH Drug Zacks
Jan-22-20 09:45AM	Biotech Stock Roundup: Updates From HZNP & CLVS, BioNTech to Acquire Neon Zacks +5.30%
09:33AM	3 Healthcare Stocks With Important Catalysts in Q1 TipRanks
Jan-15-20 08:00AM	Kala Pharmaceuticals Announces Completion of Enrollment of STRIDE 3 Trial for EYSUVIS (KPI-121 0.25%) for Dry Eye Disease Business Wire
Jan-14-20 09:21AM	Investors Who Bought Kala Pharmaceuticals (NASDAQ:KALA) Shares A Year Ago Are Now Down 13% Simply Wall St.
Jan-08-20 08:00AM	Kala Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference Business Wire +9.28%
Dec-19-19 09:53PM	Is Kala Pharmaceuticals, Inc. (KALA) A Good Stock To Buy? Insider Monkey
04:05PM	Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Dec-12-19 04:11PM	3 Biotech Stocks That Offer the Highest Upside on Wall Street TipRanks +12.86%
Nov-19-19 04:05PM	Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Nov-07-19 08:25AM	Kala Pharmaceuticals (KALA) Reports Q3 Loss, Misses Revenue Estimates Zacks
07:00AM	Kala Pharmaceuticals Reports Third Quarter 2019 Financial Results Business Wire
Nov-04-19 04:30PM	Kala Pharmaceuticals to Report Third Quarter 2019 Financial Results and Host Conference Call Business Wire
Oct-21-19 04:05PM	Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Oct-11-19 08:34AM	What Kind Of Shareholders Own Kala Pharmaceuticals, Inc. (NASDAQ:KALA)? Simply Wall St.
Sep-25-19 08:40AM	Implied Volatility Surging for Kala Pharmaceuticals (KALA) Stock Options Zacks
Sep-19-19 04:05PM	Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bazemore Todd	Chief Operating Officer	Oct 22	Buy	7.60	40	304	42	Oct 28 08:36 PM
Trachtenberg Eric	See Remarks	Jun 19	Option Exercise	5.19	28,901	149,996	28,901	Jun 22 04:06 PM
Reumuth Mary	Chief Financial Officer	Jun 09	Option Exercise	2.64	43,477	114,771	48,293	Jun 11 04:58 PM
Bazemore Todd	Chief Operating Officer	Jun 05	Buy	13.39	2	27	2	Oct 28 08:36 PM
Brazzell Romulus K	Chief Medical Officer	Apr 09	Option Exercise	2.99	67,771	202,377	176,496	Apr 13 08:38 AM
Chen Hongming	Chief Scientific Officer	Mar 30	Option Exercise	2.30	31,000	71,300	86,849	Apr 01 04:43 PM
Bazemore Todd	Chief Operating Officer	Mar 16	Buy	5.75	10,000	57,500	10,000	Mar 17 05:46 PM
Grunberg Gregory	Director	Mar 13	Buy	7.89	2,534,854	19,999,998	2,534,854	Mar 16 07:59 AM
Shah Rajeev M.	Director	Mar 13	Buy	7.89	6,337,135	49,999,995	10,874,613	Mar 13 06:47 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 13	Buy	7.89	6,337,135	49,999,995	10,874,613	Mar 13 06:45 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience